A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor

Innovent Biologics

Status and phase: Terminated; Phase 1

Conditions: Myeloid Tumor

Treatments: Drug: IBI322

Study type: Interventional

Funder types: Industry

Identifiers

NCT05148442

CIBI322A106

Details and patient eligibility

About

This is a phase I study evaluating the safety, tolerability and preliminary efficacy of IBI322 in Myeloid tumor patients.

Full description

Phase 1a/1b study will be conducted to evaluate the tolerability, safety, PK, PD, immunogenicity and preliminary antitumor activity of IBI322 in patients with myeloid tumor. Phase 1a is the dose escalation part of the study and Phase 1b is the dose expansion part. Combination therapy with HMA(Azacitidine or Decitabine) will be evaluated.

Enrollment: 1 patient

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients who met the diagnostic criteria of recurrent / refractory AML (WHO 2016)(primordial cells in bone marrow ≥ 5%) (excluding APL and bcr-abl positive AML ) and underwent treatment.
2. Patients who meet the diagnostic criteria of recurrent / refractory MDS (WHO 2016)and underwent treatment.
3. Patients with recurrent / refractory Essential thrombocythemia (WHO2016) after treatment (for Phase Ia)
4. Male or female subject above 18 years old
5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) performance status 0 ~ 2.
6. Must have adequate organ function

Exclusion criteria

1. Previous history with myeloproliferative Neoplasms(MPN) or MDS/MPN
2. Transformation or treatment related AML/MDS.
3. PV/MF/AML/MDS evolved from Essential thrombocythemia
4. Relapse after allogeneic hematopoietic stem cell transplantation, or autologous hematopoietic stem cell transplantation within 1 year
5. Central nervous system leukemia infiltration
6. Previous history of chronic hemolytic anemia or screening Coombe test positive
7. Previous exposure to any anti-CD47 monoclonal antibody, SIRPα antibody, or CD47/SIRPα recombinant protein.
8. Previous exposure to chimeric antigen receptor T cell immunotherapy (CAR-T)
9. Patients who received immunotherapy, targeted therapy, biological therapy or any clinical research treatment within 14 days before receiving the first dose
10. Uncontrolled concurrent diseases
11. Subjects who are allergic to the ingredients of the study drug
12. Subjects who have used immunosuppressive drugs within 7 days before the first dose of study treatment

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

1 participants in 1 patient group

IBI322

Experimental group

Treatment:

Drug: IBI322